Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 10, 2022

SELL
$2.11 - $7.25 $85,455 - $293,625
-40,500 Reduced 21.5%
147,857 $367,000
Q4 2021

Feb 04, 2022

BUY
$5.18 - $7.24 $77,700 - $108,600
15,000 Added 8.65%
188,357 $1.13 Million
Q3 2021

Nov 10, 2021

BUY
$5.01 - $7.58 $27,555 - $41,690
5,500 Added 3.28%
173,357 $1.16 Million
Q2 2021

Aug 10, 2021

BUY
$6.65 - $10.04 $66,500 - $100,399
10,000 Added 6.33%
167,857 $1.12 Million
Q1 2021

May 11, 2021

BUY
$9.1 - $19.57 $200,263 - $430,676
22,007 Added 16.2%
157,857 $1.46 Million
Q3 2020

Dec 10, 2020

BUY
$4.25 - $14.19 $850 - $2,838
200 Added 0.15%
135,850 $1.93 Million
Q2 2020

Aug 10, 2020

BUY
$0.78 - $5.1 $105,807 - $691,815
135,650 New
135,650 $680,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $171M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Mercer Global Advisors Inc Portfolio

Follow Mercer Global Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.